A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

Cancer Journal

Volumn 8, Issue 5, 2002, Pages 395-399

  Kulke, Matthew H ^a   Demetri, George D ^a   Sharpless, Norman E ^a   Ryan, David P ^b   Shivdasani, Ramesh ^a   Clark, Jeffrey S ^b   Spiegelman, Bruce M ^a   Kim, Haesook ^a   Mayer, Robert J ^a   Fuchs, Charles S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Differentiation; Peroxisome proliferator activated receptor ; Thiazolidinedione

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CELL RECEPTOR; CHROMAN DERIVATIVE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; COLORECTAL TUMOR; DISEASE COURSE; DRUG POTENTIATION; DRUG RESISTANCE; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMANS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SURVIVAL ANALYSIS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036730017     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200209000-00010     Document Type: Article

References (19)

1. Tontonez P, Hu E, Spiegelman B. Stimulation of adipogenesis in fibroblasts by PPAR-γ2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
2. Braissant O, Fouffelle F, Scott C et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and -gamma in the adult rat. Endocrinology 1996;137:354-366.
3. Tontonez P, Hu E, Graves R et al. mPPAR gamma 2: tissue-specific regulator of an adopocyte enhancer. Genes Dev 1994;8:1224-1234.
4. Ricote M, Li A, Willson T et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
5. Auboef D. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997;46:1319-1327.
6. Tontonez P, Singer S, Forman B et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997;94:237-241.
7. Mueller E, Sarraf P, Tontonez P et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998;1:465-470.
8. Sarraf P, Mueller E, Jones D et al. Differentiation and reversal of malignant changes in colon cancer through PPAR. Nat Med 1998;4:1046-10-57.
9. Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000;67:2405-2416.
10. Itami A, Watanabe G, Shimada Y et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer 2001;94:370-376.
11. Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-1361.
12. Warrell R, Frankel S, Miller W et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991;324:1385-1393.
13. Demetri G, Fletcher C, Mueller E et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999;96:3951-56.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Gale E. Lessons from the glitazones: a story of drug development. Lancet 2001;377:1870-1805.
16. Ryan D, Kulke M, Fuchs C et al. Biweekly oxaliplatin in combination with a modified DeGramont 5FU/leucovorin regimen in previously treated patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 2001;20:A560.
17. Saez E, Tontonoz P, Nelson M et al. Activators of the nuclear receptor PPAR enhance colon polyp formation. Nat Med 1998;4:1058-1061.
18. Lefebvre A, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor promotes the development of colon tumors in C57BL/6J-APCmin/+ mice. Nat Med 1998;4:1053-1057.
19. Seed B. PPAR and colorectal carcinoma: conflicts in a nuclear family. Nat Med 1998;4:1004-1005.